Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Libra

Showing results (261-270 of 280) with videos related to

Pageof 28
Sort By:
Oncotarget|October 23, 2012
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistanceJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Communications Biology|April 8, 2023
Proton boron capture therapy (PBCT) induces cell death and mitophagy in a heterotopic glioblastoma modelFrancesco Paolo Cammarata, Filippo Torrisi, Nunzio Vicario, et al.
BMC Cancer|January 25, 2017
Low glycemic index diet, exercise and vitamin D to reduce breast cancer recurrence (DEDiCa): design of a clinical trialLivia S A Augustin, Massimo Libra, Anna Crispo, et al.
Cancer Research|June 29, 2017
Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ SignalingMarco Donia, Katja Harbst, Marit van Buuren, et al.
Advances in Biological Regulation|November 6, 2019
Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cellsShaw M Akula, Saverio Candido, Stephen L Abrams, et al.
Aging|March 23, 2011
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and agingLinda S Steelman, William H Chappell, Stephen L Abrams, et al.
Advances in Biological Regulation|May 4, 2019
Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cellsShaw M Akula, Saverio Candido, Massimo Libra, et al.
Advances in Biological Regulation|March 23, 2019
Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticalsSaverio Candido, Stephen L Abrams, Linda S Steelman, et al.
Oncotarget|July 23, 2014
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic interventionNicole M Davis, Melissa Sokolosky, Kristin Stadelman, et al.
Oncotarget|March 18, 2011
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human healthWilliam H Chappell, Linda S Steelman, Jacquelyn M Long, et al.
Pageof 28

Showing results (261-270 of 280) with videos related to

Sort By:
Pageof 28
Oncotarget|October 23, 2012
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistanceJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Communications Biology|April 8, 2023
Proton boron capture therapy (PBCT) induces cell death and mitophagy in a heterotopic glioblastoma modelFrancesco Paolo Cammarata, Filippo Torrisi, Nunzio Vicario, et al.
BMC Cancer|January 25, 2017
Low glycemic index diet, exercise and vitamin D to reduce breast cancer recurrence (DEDiCa): design of a clinical trialLivia S A Augustin, Massimo Libra, Anna Crispo, et al.
Cancer Research|June 29, 2017
Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ SignalingMarco Donia, Katja Harbst, Marit van Buuren, et al.
Advances in Biological Regulation|November 6, 2019
Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cellsShaw M Akula, Saverio Candido, Stephen L Abrams, et al.
Aging|March 23, 2011
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and agingLinda S Steelman, William H Chappell, Stephen L Abrams, et al.
Advances in Biological Regulation|May 4, 2019
Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cellsShaw M Akula, Saverio Candido, Massimo Libra, et al.
Advances in Biological Regulation|March 23, 2019
Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticalsSaverio Candido, Stephen L Abrams, Linda S Steelman, et al.
Oncotarget|July 23, 2014
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic interventionNicole M Davis, Melissa Sokolosky, Kristin Stadelman, et al.
Oncotarget|March 18, 2011
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human healthWilliam H Chappell, Linda S Steelman, Jacquelyn M Long, et al.
Pageof 28